Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess the Safety and the Efficacy of Extracorporeal Photopheresis Using the Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

NCT03083574 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT03083574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03083574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess the Safety and the Efficacy of Extracorporeal Photopheresis Using the Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2014
Completion date
September 30, 2023
Enrollment
100 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

refractory chronic graft versus host disease (cgvhd)